[The cerebral blood-flow-volume in patients with sclerotic changes after treatment with raubasin (Lamuran)].
D000284:Administration, Oral; D000368:Aged; D001158:Arteries; D002245:Carbon Dioxide / Q000097:blood; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D002537:Intracranial Arteriosclerosis / Q000175:diagnosis / Q000188:drug therapy*; D010313:Partial Pressure; D008517:Phytotherapy; D010919:Placebos; D010946:Plants, Medicinal; D011868:Radioisotopes; D011877:Radionuclide Imaging; D011926:Rauwolfia / Q000009:adverse effects / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects; D046948:Secologanin Tryptamine Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D014978:Xenon
D010919:Placebos; D011868:Radioisotopes; D046948:Secologanin Tryptamine Alkaloids; D002245:Carbon Dioxide; D014978:Xenon
Das Verhalten des Hirndurchblutungsvolumens unter Behandlung mit Raubasin (Lamuran) bei Sklerose der Zerebralgefässe